Quizartinib
- Generic Name
- Quizartinib
- Brand Names
- Vanflyta
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32N6O4S
- CAS Number
- 950769-58-1
- Unique Ingredient Identifier
- 7LA4O6Q0D3
- Background
Quizartinib is an oral and potent fms-like tyrosine kinase 3 (FLT3) inhibitor and it is the first drug developed specifically targeting FLT3, as other agents with FLT3 inhibition activities were investigated with other targets in mind. Additionally, quizartinib also demonstrates inhibitory activity toward FLT3 with internal tandem duplication (ITD), although...
- Indication
Quizartinib is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-appr...
- Associated Conditions
- Newly Diagnosed Acute Myeloid Leukemia (AML)
- Associated Therapies
- -
A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
- First Posted Date
- 2019-12-24
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 1
- Registration Number
- NCT04209725
- Locations
- 🇺🇸
HCA Midwest, Kansas City, Missouri, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 52
- Registration Number
- NCT04128748
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment
- Conditions
- Interventions
- First Posted Date
- 2019-10-02
- Last Posted Date
- 2022-03-14
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 63
- Registration Number
- NCT04112589
- Locations
- 🇪🇸
Hospital General Universitario de Alicante, Alicante, Spain
🇪🇸Institut Català D'Oncologia-Hospital Germans Trias I Pujol, Badalona, Spain
🇪🇸Institut Català D'Oncologia-Hospital Duran I Reynals, Bellvitge, Spain
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2019-09-27
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 273
- Registration Number
- NCT04107727
- Locations
- 🇪🇸
Hospital Universitari i Politecnic La Fe, Valencia, Spain
🇪🇸Hospital Clínico Universitario de Valladolid, Valladolid, Spain
🇪🇸Hospital Universitario Miguel Servet, Zaragoza, Spain
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Conditions
- Recurrent Acute Biphenotypic LeukemiaAcute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaBlasts 20 Percent or More of Bone Marrow Nucleated CellsRefractory Acute Myeloid LeukemiaRefractory High Risk Myelodysplastic SyndromeHigh Risk Myelodysplastic SyndromeRecurrent High Risk Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2019-08-07
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT04047641
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
- Conditions
- Interventions
- First Posted Date
- 2019-01-04
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 65
- Registration Number
- NCT03793478
- Locations
- 🇺🇸
Loma Linda University Cancer Center, Loma Linda, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT03735875
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- First Posted Date
- 2018-10-29
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 7
- Registration Number
- NCT03723681
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, China
Quizartinib, Decitabine, and Venetoclax in Treating Participants with Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 73
- Registration Number
- NCT03661307
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)
- First Posted Date
- 2018-06-11
- Last Posted Date
- 2022-05-20
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 10
- Registration Number
- NCT03552029
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸Duke University Cancer Center, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.